MedTrace Logo

ArtiSential® for Rectal Cancer Surgery

NCT06236282 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93

Last updated 2024-02-01

No results posted yet for this study

Summary

This study aimed to assess efficacy of ArtiSential® in reducing laparoscopic rectal cancer surgery duration. We retrospectively reviewed the data of patients who underwent laparoscopic low or ultralow anterior resection for primary mid-to-low rectal cancer, performed by a single surgeon in 2012-2022. Patients were divided into groups, use group vs. non-use group, based on the use or non-use of the ArtiSential®. The total mesorectal excision quality and resection margin status did not differ between the groups. ArtiSential® reduced operative time without impairing surgical quality or oncologic outcomes.

Conditions

Interventions

DEVICE

ArtiSential®

Articulated laparoscopic device made by Livsmed Co, South Korea.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-01
Primary Completion
2022-12-31
Completion
2023-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06236282 on ClinicalTrials.gov